Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment

• 2024

  Log in to bookmark this resource.

  Log in
• Ashley Cirillo; Stephanie Gaw
PMID: 39437376DOI: https://dx.doi.org/10.1097/OGX.0000000000001324

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article provides guidance on preventing respiratory syncytial virus (RSV) in infants. It describes two new FDA-approved options: Beyfortus, a monoclonal antibody for infants, and Abrysvo, a maternal vaccine. The article reviews guidelines from major health organizations recommending RSV vaccination for pregnant individuals during the RSV season. If mothers are not vaccinated or vaccinated less than 14 days before birth, their infants should receive the monoclonal antibody. Both methods can reduce infant infections significantly. Future studies will explore additional protection strategies like cocooning and breast milk's role in immunity.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antibodies, Monoclonal; Infant; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Respiratory Syncytial Viruses; United States; Vaccination; Respiratory Syncytial Virus Vaccines

Institutions: University of California San Francisco

---

More like this

Strategies Used by Children’s Hospitals During the 2022 Viral Respiratory Surge 2025 · Seattle Children's Hospital, Ann and Robert H. Lurie Children’s Hospital, University of California San Francisco, UCSF Benioff Children's Hospital, St. Joseph’s Health, Boston Children's Hospital, University of Washington, Pediatric Pandemic Network (PPN) Review of Pediatric Emergency Care and the COVID-19 Pandemic 2023 · University of California San Francisco, Children's Hospital of Philadelphia, Texas Children's Hospital, Children's National Hospital, University of California, Los Angeles Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates 2025 · University of California San Francisco

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---